ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

NCI To Expand SPORE Grants Program to Increase Translational Research Funding

October 22, 1999

Columbia Next for comprehensive Center Review

February 18, 1977

DCT Board Oks Limited Support For Development Of Neutron Therapy

March 31, 1978

Deflecting Earmarks, NCI Advisors Lay Out Research Opportunities In Breast, Prostate

February 26, 1999

Schepartz New DCT Deputy Director; DeVita To Continue As Clinical Director

September 3, 1976

NCCS Networker Volume 8 Issue 2, Summer 1994

June 13, 1994